Valuation: Ocugen, Inc.

Capitalization 60Cr 51Cr 47Cr 44Cr 82Cr 5.59TCr 83Cr 548.02Cr 215.67Cr 2.68TCr 224.33Cr 219.7Cr 9.53TCr P/E ratio 2026 *
-8.15x
P/E ratio 2027 * -9.94x
Enterprise value 56Cr 48Cr 44Cr 41Cr 76Cr 5.24TCr 78Cr 513.38Cr 202.04Cr 2.52TCr 210.15Cr 205.82Cr 8.93TCr EV / Sales 2026 *
392x
EV / Sales 2027 * 14.3x
Free-Float
98.55%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocugen, Inc.

1 day-4.32%
1 week-1.67%
Current month-2.21%
1 month-13.24%
3 months+18.79%
6 months+12.74%
Current year+31.11%
1 week 1.67
Extreme 1.67
2.04
1 month 1.67
Extreme 1.67
2.29
Current year 1.31
Extreme 1.31
2.72
1 year 0.64
Extreme 0.64
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 27/09/2019
Director of Finance/CFO - 09/02/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 62 27/09/2019
Director/Board Member 59 01/09/2013
Director/Board Member 59 01/09/2019
Change 5d. change 1-year change 3-years change Capi.($)
-4.32%-1.67%+161.41%+125.16% 60Cr
-0.70%-5.17%-7.83%-12.51% 4.57TCr
-1.81%+0.75%+36.25%+20.84% 3.46TCr
+1.83%+1.29%+307.28%+513.01% 3.13TCr
-0.61%+0.23%+24.41%-13.16% 2.95TCr
-1.22%+1.96%+34.13%+31.79% 2.88TCr
-2.07%-0.59%+51.00%+201.23% 1.48TCr
-2.56%-0.98%+78.17%+172.42% 1.47TCr
-8.71%-8.84%+28.27%+3.77% 1.43TCr
+1.07%-5.68%+3,621.17%+3,898.31% 1.4TCr
Average -1.91%-0.90%+433.43%+494.09% 2.28TCr
Weighted average by Cap. -1.19%-0.55%+286.59%+337.60%

Financials

2026 *2027 *
Net sales 14.29L 12.15L 11.15L 10.58L 19.5L 13Cr 19.93L 1.31Cr 51.52L 6.41Cr 53.58L 52.48L 23Cr 4.19Cr 3.57Cr 3.27Cr 3.1Cr 5.72Cr 392.23Cr 5.85Cr 38Cr 15Cr 188.21Cr 16Cr 15Cr 668.4Cr
Net income -7.06Cr -6.01Cr -5.51Cr -5.23Cr -9.64Cr -660.74Cr -9.86Cr -65Cr -25Cr -317.05Cr -26Cr -26Cr -1.13TCr -5.51Cr -4.68Cr -4.3Cr -4.08Cr -7.52Cr -515.08Cr -7.68Cr -50Cr -20Cr -247.16Cr -21Cr -20Cr -877.75Cr
Net Debt -3.78Cr -3.22Cr -2.95Cr -2.8Cr -5.16Cr -353.62Cr -5.27Cr -35Cr -14Cr -169.68Cr -14Cr -14Cr -602.6Cr -
Logo Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Employees
116
Date Price Change Volume
21/26/21 1.770 $ -4.32% 40,09,583
20/26/20 1.850 $ -7.04% 1,16,41,336
17/26/17 1.990 $ +3.11% 51,93,729
16/26/16 1.930 $ -1.03% 48,05,962
15/26/15 1.950 $ +8.33% 59,99,558
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.770USD
Average target price
11.57USD
Spread / Average Target
+553.75%

Quarterly revenue - Rate of surprise